Furthermore, GLP-1 drugs had a favorable safety profile versus aspirin, particularly with respect to bleeding events, said ...

Meanwhile, in attempts to address long-standing thyroid cancer concerns, a research team conducted a 350,000-person analysis ...

Among adolescents with asthma and overweight or obesity, the relative risk for acute asthma exacerbations was significantly reduced with GLP-1 receptor agonist use vs. nonpharmacological weight ...

Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like ...

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users.

A study by Mass General Brigham, published in the JAMA medical journal, found that discontinuing popular weight loss ...

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than ...

Some dietary supplements may help naturally boost GLP-1, but more research is needed to better understand their potential ...